Abacus FCF Advisors LLC Buys 92,945 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Abacus FCF Advisors LLC increased its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 369.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 118,090 shares of the company's stock after purchasing an additional 92,945 shares during the period. Abacus FCF Advisors LLC owned 0.05% of Hims & Hers Health worth $3,490,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of HIMS. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares during the last quarter. UMB Bank n.a. increased its stake in shares of Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after acquiring an additional 933 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Summit Securities Group LLC bought a new position in Hims & Hers Health during the 4th quarter worth approximately $38,000. Finally, US Bancorp DE boosted its stake in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after acquiring an additional 1,508 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Leerink Partners boosted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Bank of America lifted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Piper Sandler reaffirmed a "neutral" rating and issued a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Saturday. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $38.00.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $1.71 during midday trading on Tuesday, reaching $55.15. The company's stock had a trading volume of 38,232,363 shares, compared to its average volume of 20,824,061. The company has a market cap of $12.35 billion, a P/E ratio of 125.35 and a beta of 2.09. The business's 50 day moving average price is $42.75 and its two-hundred day moving average price is $37.55. Hims & Hers Health, Inc. has a fifty-two week low of $13.47 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business's revenue for the quarter was up 110.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.05 earnings per share. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Melissa Baird sold 33,333 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $25.78, for a total transaction of $859,324.74. Following the completion of the sale, the chief operating officer now directly owns 805,083 shares in the company, valued at approximately $20,755,039.74. This trade represents a 3.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $33.98, for a total value of $4,353,755.46. Following the completion of the transaction, the chief executive officer now directly owns 173,655 shares of the company's stock, valued at approximately $5,900,796.90. This trade represents a 42.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 622,467 shares of company stock valued at $25,513,488 in the last quarter. Insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.